News By Tag
News By Location
tebu-bio to become Enzium’s European distributor for protease assays
tebu-bio is pleased to announce their agreement with Enzium to distribute their innovative products for measuring protease activities with a non-FRET technology throughout Europe
Enzium Inc. (Philadelphia, PA, USA) has developed a new approach to measure the activity of proteases such as diverse MMPs, ADAMs, Thrombin, Factor Xa, and Furin and the inhibitory effects of drug candidates.
Dr. Diana Hulboy (VP, Marketing and Business Development at Enzium) says: "We are thrilled to collaborate with tebu-bio on the marketing of EnSens® assays throughout the European community, as we believe our new, non-FRET fluorescent technology will change how researchers think about protease activity detection."
Dr. Ali El Bayâ (tebu-bio, Sales Manager – Proteins & Protein based Products & Services) adds "Enzium’s EnSens® technology is a very promising alternative to classical FRET based protease assays which are used in screenings in drug discovery. The benefits of this new approach in terms of lower signal to noise ratio and higher flexibility in creating longer and more complex protease recognition sites seem obvious to us. We are sure our extensive customer base within the drug discovery community will be keen to use this technology."
To find out more about Enzium’s products available from tebu-bio, visit http://www.tebu-
tebu-bio is a pan-European company with 9 local offices throughout Europe, specialised in providing innovative reagents and laboratory services in Life Sciences. For more than ten years now, tebu-bio's own laboratories operating in France provide researchers with an ever-growing offer of standard or custom lab services.
tebu-bio is an active member of recognised professional networks and clusters (Medicen, Cosmetic Valley...), and received the PM’up award in the Health/Life Sciences sector, attributed to dynamic, high-potential companies by the “Région Ile-de-France”
Enzium, Inc., based in Philadelphia, PA, USA, was founded in 2011 on its EnSens® fluorescent protease activity detection technology. Enzium is dedicated to developing fluorescent based reagents for highly selective protease activity detection using its proprietary modular protein and dye technology. It is Enzium’s goal to enable its customers to easily integrate the same assay in applications across entire research, drug, and diagnostic development pipelines.